ADVERTISEMENT
  • News
  • New York
  • Technology
  • Culture
  • Entertainment
  • Sport
  • More
    • Politics
    • Lifestyle
    • TV
    • Games
Friday, June 13, 2025
  • Login
No Result
View All Result
NEWSLETTER
FINCHANNEL
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
No Result
View All Result
FINCHANNEL
No Result
View All Result
Home Health&Beauty

FDA Takes Further Steps to Confront Opioid Crisis Through Risk Evaluation and Mitigation Strategy Programs

The FINANCIAL by The FINANCIAL
December 25, 2020
in Health&Beauty
Reading Time: 3 mins read
9
A A
0
Share on FacebookShare on Twitter

The FINANCIAL — While our efforts to combat COVID-19 remain at the forefront of our day-to-day activities, the U.S. Food and Drug Administration also continues its work on a number of important public health issues and, in particular, the opioid crisis. We remain committed to using all facets of our regulatory authority to lessen the impact of opioid addiction, misuse, and abuse while also striking a careful balance between patient access and safety to ensure that patients suffering from significant pain have access to appropriate medication.

According to FDA, to that end, the FDA has been and continues to address this public health crisis on a number of fronts, including efforts to:

Decrease unnecessary exposure to prescription opioids and prevent new addiction;
Support the treatment of those with opioid use disorder;
Foster the development of new and effective pain therapies; and
Take action against those who contribute to the illegal importation and sale of opioid products.
Part of our regulatory authority efforts include requiring Risk Evaluation and Mitigation Strategies (REMS) for various opioid analgesics to help mitigate the serious risks associated with their use.

According to FDA, they took further steps to strengthen the REMS program for transmucosal immediate-release fentanyl (TIRF) products to help ensure that the benefits of these drugs continue to outweigh the risks.

TIRF medicines contain fentanyl, a powerful opioid, and are used to manage breakthrough pain in adults with cancer who are routinely taking other opioid pain medicines around-the-clock for pain. To use the TIRF medicines safely, these patients must be opioid tolerant based on concurrent regular use of another opioid medication.

Despite the decline in the use of TIRF medicines in recent years, data have suggested that prescribing of TIRF medicines still occurs in patients who are not opioid tolerant. With this in mind, the FDA finalized modifications to the REMS program to address the persistence of these concerning prescribing practices. These changes will also improve our ability to monitor for adverse events and ensure safe use of these medicines.

In particular, this program has been strengthened to:

Require that prescribers document a patient’s opioid tolerance with each prescription of a TIRF medicine for outpatient use;
Require outpatient pharmacies dispensing TIRF medicines to document and verify a patient’s opioid tolerance before dispensing;
Require inpatient pharmacies to develop internal policies and procedures to verify opioid tolerance in patients who require TIRF medicines while hospitalized; and

Require a new patient registry for use, along with other data sources, to monitor for accidental exposure, misuse, abuse, addiction, and overdose.
In addition to the modifications to fortify the TIRF REMS program, the FDA also continues efforts to evaluate the opioid analgesic (OA) REMS. Earlier this month, we hosted a workshop inviting scientific discussions about methods to evaluate the impact of the OA REMS on prescriber behavior and patient outcomes. The goal of the OA REMS is to educate prescribers and other health care providers (including pharmacists) on the treatment and monitoring of patients with pain. The public workshop served as a forum for public scientific discussion of innovative, multidisciplinary methods to consider when evaluating the OA REMS education program. The FDA will use these discussions to ensure that the methods ultimately used to evaluate the OA REMS are scientifically sound.

Effectively addressing the opioid crisis requires continued focus and collaboration across many different stakeholders. The FDA’s REMS are an important tool, and it’s critical we ensure they are continuing to fulfill their purpose.

RelatedPosts

Fullscript vs. Rupa Health: What the Acquisition Means for Providers and Patients

Signs Your Mental Health Is in Trouble and How to Fix It

Packaged bread can be considered ultra-processed foods

As many as 30% of people with insomnia report using alcohol as a sleep aid

The FINANCIAL — While our efforts to combat COVID-19 remain at the forefront of our day-to-day activities, the U.S. Food and Drug Administration also continues its work on a number of important public health issues and, in particular, the opioid crisis. We remain committed to using all facets of our regulatory authority to lessen the impact of opioid addiction, misuse, and abuse while also striking a careful balance between patient access and safety to ensure that patients suffering from significant pain have access to appropriate medication.

See also  Fullscript vs. Rupa Health: What the Acquisition Means for Providers and Patients

According to FDA, to that end, the FDA has been and continues to address this public health crisis on a number of fronts, including efforts to:

Decrease unnecessary exposure to prescription opioids and prevent new addiction;
Support the treatment of those with opioid use disorder;
Foster the development of new and effective pain therapies; and
Take action against those who contribute to the illegal importation and sale of opioid products.
Part of our regulatory authority efforts include requiring Risk Evaluation and Mitigation Strategies (REMS) for various opioid analgesics to help mitigate the serious risks associated with their use.

According to FDA, they took further steps to strengthen the REMS program for transmucosal immediate-release fentanyl (TIRF) products to help ensure that the benefits of these drugs continue to outweigh the risks.

TIRF medicines contain fentanyl, a powerful opioid, and are used to manage breakthrough pain in adults with cancer who are routinely taking other opioid pain medicines around-the-clock for pain. To use the TIRF medicines safely, these patients must be opioid tolerant based on concurrent regular use of another opioid medication.

Despite the decline in the use of TIRF medicines in recent years, data have suggested that prescribing of TIRF medicines still occurs in patients who are not opioid tolerant. With this in mind, the FDA finalized modifications to the REMS program to address the persistence of these concerning prescribing practices. These changes will also improve our ability to monitor for adverse events and ensure safe use of these medicines.

In particular, this program has been strengthened to:

Require that prescribers document a patient’s opioid tolerance with each prescription of a TIRF medicine for outpatient use;
Require outpatient pharmacies dispensing TIRF medicines to document and verify a patient’s opioid tolerance before dispensing;
Require inpatient pharmacies to develop internal policies and procedures to verify opioid tolerance in patients who require TIRF medicines while hospitalized; and

Require a new patient registry for use, along with other data sources, to monitor for accidental exposure, misuse, abuse, addiction, and overdose.
In addition to the modifications to fortify the TIRF REMS program, the FDA also continues efforts to evaluate the opioid analgesic (OA) REMS. Earlier this month, we hosted a workshop inviting scientific discussions about methods to evaluate the impact of the OA REMS on prescriber behavior and patient outcomes. The goal of the OA REMS is to educate prescribers and other health care providers (including pharmacists) on the treatment and monitoring of patients with pain. The public workshop served as a forum for public scientific discussion of innovative, multidisciplinary methods to consider when evaluating the OA REMS education program. The FDA will use these discussions to ensure that the methods ultimately used to evaluate the OA REMS are scientifically sound.

Effectively addressing the opioid crisis requires continued focus and collaboration across many different stakeholders. The FDA’s REMS are an important tool, and it’s critical we ensure they are continuing to fulfill their purpose.

Tags: and abuse while also striking a careful balance between patient access and safety to ensure that patients suffering from significant pain have access to appropriate medicationFDAfood and drug administrationin particularmisuseOA REMSRisk Evaluation and Mitigation Strategiesthe opioid crisis. We remain committed to using all facets of our regulatory authority to lessen the impact of opioid addictionthe U.S. Food and Drug Administration also continues its work on a number of important public health issues andWhile our efforts to combat COVID-19 remain at the forefront of our day-to-day activities

Related Posts

Fullscript vs. Rupa Health: What the Acquisition Means for Providers and Patients
Health&Beauty

Fullscript vs. Rupa Health: What the Acquisition Means for Providers and Patients

by The FINANCIAL
June 11, 2025
0

In a significant move that reshapes the healthcare landscape, Fullscript, a leading healthcare platform for whole person care, announced the...

Read more
Signs Your Mental Health Is in Trouble and How to Fix It

Signs Your Mental Health Is in Trouble and How to Fix It

May 28, 2025
Packaged bread can be considered ultra-processed foods

Packaged bread can be considered ultra-processed foods

April 29, 2025
Chronic sleep deficiency increases insulin resistance in women, especially postmenopausal women

As many as 30% of people with insomnia report using alcohol as a sleep aid

April 16, 2025

Discussion about this post

  • Trending
  • Comments
  • Latest
Domestic tourism numbers decreased in Georgia

Georgian economy contracted by 5.5 % in July 2020

August 31, 2020
Ampersand wins £22m five-year contract at London Zoo

Ampersand wins £22m five-year contract at London Zoo

June 25, 2012
Fullscript vs. Rupa Health: What the Acquisition Means for Providers and Patients

Fullscript vs. Rupa Health: What the Acquisition Means for Providers and Patients

June 11, 2025
Will digital media be decisive in general election – as it was in Donald Trump’s victory? 

How to Align Social Media with Your Overall Marketing Strategy

June 11, 2025
Leon Botstein’s Five-Decade Transformation at Bard College

Leon Botstein’s Five-Decade Transformation at Bard College

May 28, 2025
New World Bank Group Country Director for Belarus, Moldova and Ukraine Welcomes Reform Efforts in Moldova

Moldova urged to strengthen protection of vulnerable victims

June 11, 2025
Will digital media be decisive in general election – as it was in Donald Trump’s victory? 

How to Align Social Media with Your Overall Marketing Strategy

June 11, 2025
Presence of minority languages in media and education in Slovenia should be strengthened, Council of Europe

Presence of minority languages in media and education in Slovenia should be strengthened, Council of Europe

June 11, 2025
How to Avoid Common Loan Mistakes: A Borrower’s Guide

How to Avoid Common Loan Mistakes: A Borrower’s Guide

June 11, 2025
7 Ways to Improve Your Business Finances

7 Ways to Improve Your Business Finances

June 11, 2025
ADVERTISEMENT

Popular Last 24h

  • Fullscript vs. Rupa Health: What the Acquisition Means for Providers and Patients

    Fullscript vs. Rupa Health: What the Acquisition Means for Providers and Patients

    46 shares
    Share 18 Tweet 12
  • Georgian economy contracted by 5.5 % in July 2020

    110 shares
    Share 44 Tweet 28
  • Ampersand wins £22m five-year contract at London Zoo

    3564 shares
    Share 1426 Tweet 891
  • The London Diplomatic List, Addresses, Contacts & Working Hours

    3082 shares
    Share 1233 Tweet 771
  • More than a third of UK office workers have no dedicated workspace at home

    135 shares
    Share 54 Tweet 34
  • Sharon Srivastava and the Human Cost of a Digital Disinformation Campaign

    26 shares
    Share 10 Tweet 7
  • Leon Botstein’s Five-Decade Transformation at Bard College

    288 shares
    Share 115 Tweet 72

LATEST POSTS

New World Bank Group Country Director for Belarus, Moldova and Ukraine Welcomes Reform Efforts in Moldova

Moldova urged to strengthen protection of vulnerable victims

June 11, 2025
Will digital media be decisive in general election – as it was in Donald Trump’s victory? 

How to Align Social Media with Your Overall Marketing Strategy

June 11, 2025
Presence of minority languages in media and education in Slovenia should be strengthened, Council of Europe

Presence of minority languages in media and education in Slovenia should be strengthened, Council of Europe

June 11, 2025
How to Avoid Common Loan Mistakes: A Borrower’s Guide

How to Avoid Common Loan Mistakes: A Borrower’s Guide

June 11, 2025
7 Ways to Improve Your Business Finances

7 Ways to Improve Your Business Finances

June 11, 2025
How a Chinese Copper Art Workshop from Jiande Win Hearts, Applause in Florence

How a Chinese Copper Art Workshop from Jiande Win Hearts, Applause in Florence

June 11, 2025
Fullscript vs. Rupa Health: What the Acquisition Means for Providers and Patients

Fullscript vs. Rupa Health: What the Acquisition Means for Providers and Patients

June 11, 2025
Sharon Srivastava and the Human Cost of a Digital Disinformation Campaign

Sharon Srivastava and the Human Cost of a Digital Disinformation Campaign

June 11, 2025
Hungary: Postponement of the foreign agent-style law is a first step, EFJ calls for its withdrawal

Hungary: Postponement of the foreign agent-style law is a first step, EFJ calls for its withdrawal

June 10, 2025
What Today’s Digital Creators Need to Know About the Art of Hosting 

What Today’s Digital Creators Need to Know About the Art of Hosting 

June 10, 2025

LATESTBUSINESS

Dropshipping Risks: How to Avoid Copyright Infringement Issues

All You Need to Know About Renovated Shipping Containers 

by The FINANCIAL
June 5, 2025
0

Insurers Planning to Increase Investment Risk Profiles

by The FINANCIAL
June 5, 2025
0

U.S. Healthcare Leaders Expect Widespread Adoption of Artificial Intelligence by 2023

Survey Reveals Institutional Investors and Wealth Mnagers Are Increasing Their Exposure to AI

by The FINANCIAL
June 5, 2025
0

Why Tbilisi Real Estate Investing is Buzzing Right Now

Why Tbilisi Real Estate Investing is Buzzing Right Now

by The FINANCIAL
June 3, 2025
0

Protected: How EquitiesFirst and Alternative Financing Could Help Fund the Global Robotics Market Race

Protected: How EquitiesFirst and Alternative Financing Could Help Fund the Global Robotics Market Race

by The FINANCIAL
May 30, 2025
0

Voters Still Support Allowing Health Insurance To Be Sold Across State Lines

How Much Health Insurance Do You Need for Your Parents?

by The FINANCIAL
May 27, 2025
0

ESSEC partners with French AI solution Mistral AI for innovation in research and education

ESSEC partners with French AI solution Mistral AI for innovation in research and education

by The FINANCIAL
May 23, 2025
0

How biases influence CEOs throughout their careers

7 Ways a CFO’s Role Is Evolving From Number Cruncher to Strategic Advisor

by The FINANCIAL
May 23, 2025
0

GET IN TOUCH

Submit guest post/Letters to the Editor:

editor (at) finchannel.com

Sales & Marketing: (+995 558) 03 03 03 Email: marketing (at) finchannel.com

Whatsup: (+995 599) 96 52 52

Georgia:

(+995 599) 96 52 52 Email: editor (@) finchannel.com

Postal address: 17 Mtskheta str. Tbilisi, Georgia 0179 The FINANCIAL

RESOURCE

  • Work at the FINANCIAL
  • ePaper
  • Advertise in The FINANCIAL
  • Access ePaper
  • Guest posts
  • Contributed articles
  • AmericanStockNews
  • Coupon Codes
  • GLOSSY MAG
American Culture Center
ACC Partner

GUIDEBOOK

  • Meet our team
  • Invest in Georgia
  • Become contributor
  • Archive

FOLLOW US

  • Facebook
  • Twitter
  • Google+
  • Youtube
No Result
View All Result
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE

© 2025 Intelligence Group llc

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.